SCPHARMACEUTICALS INC (SCPH) Stock Price, Quote, News and Overview
NASDAQ:SCPH - Nasdaq - US8106481059 - Common Stock - Currency: USD
SCPH Quote, Performance and Key Statistics
2.6
+0.07 (+2.77%)
The current stock price of SCPH is 2.6 USD. In the past month the price increased by 13.04%. In the past year, price decreased by -44.21%.
SCPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 59.86 | 780.78B | ||
| JNJ | JOHNSON & JOHNSON | 15.53 | 375.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.07 | 307.32B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.75 | 225.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.47 | 224.59B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.31B | ||
| PFE | PFIZER INC | 7.54 | 137.25B | ||
| SNY | SANOFI-ADR | 14.4 | 135.72B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.89 | 102.91B | ||
| GSK | GSK PLC-SPON ADR | 7.16 | 79.05B | ||
| ZTS | ZOETIS INC | 26.59 | 70.23B | ||
| HLN | HALEON PLC-ADR | 22.29 | 48.25B |
Related stock screener links
About SCPH
Company Profile
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Company Info
SCPHARMACEUTICALS INC
25 Burlington Mall Road, Suite 203
Burlington MASSACHUSETTS 01803 US
CEO: John H. Tucker
Employees: 136
Phone: 16175170730
SCPHARMACEUTICALS INC / SCPH FAQ
What is the stock price of SCPHARMACEUTICALS INC today?
The current stock price of SCPH is 2.6 USD. The price increased by 2.77% in the last trading session.
What is the ticker symbol for SCPHARMACEUTICALS INC stock?
The exchange symbol of SCPHARMACEUTICALS INC is SCPH and it is listed on the Nasdaq exchange.
On which exchange is SCPH stock listed?
SCPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCPHARMACEUTICALS INC stock?
12 analysts have analysed SCPH and the average price target is 15.47 USD. This implies a price increase of 495% is expected in the next year compared to the current price of 2.6. Check the SCPHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCPHARMACEUTICALS INC worth?
SCPHARMACEUTICALS INC (SCPH) has a market capitalization of 130.73M USD. This makes SCPH a Micro Cap stock.
How many employees does SCPHARMACEUTICALS INC have?
SCPHARMACEUTICALS INC (SCPH) currently has 136 employees.
What are the support and resistance levels for SCPHARMACEUTICALS INC (SCPH) stock?
SCPHARMACEUTICALS INC (SCPH) has a support level at 2.46 and a resistance level at 2.61. Check the full technical report for a detailed analysis of SCPH support and resistance levels.
Is SCPHARMACEUTICALS INC (SCPH) expected to grow?
The Revenue of SCPHARMACEUTICALS INC (SCPH) is expected to grow by 105.73% in the next year. Check the estimates tab for more information on the SCPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SCPHARMACEUTICALS INC (SCPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SCPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SCPH, evaluating the profitability, health, valuation and growth aspects
- SCPHARMACEUTICALS INC (SCPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCPHARMACEUTICALS INC (SCPH) Sales and EPS estimates to see what analysts future expectations are.
- SCPHARMACEUTICALS INC (SCPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCPHARMACEUTICALS INC (SCPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCPHARMACEUTICALS INC (SCPH) Stock Chart to make your own analysis
- SCPHARMACEUTICALS INC (SCPH) Latest news and press-releases to stay up to date.
Does SCPHARMACEUTICALS INC (SCPH) stock pay dividends?
SCPH does not pay a dividend.
When does SCPHARMACEUTICALS INC (SCPH) report earnings?
SCPHARMACEUTICALS INC (SCPH) will report earnings on 2025-05-20, after the market close.
What is the Price/Earnings (PE) ratio of SCPHARMACEUTICALS INC (SCPH)?
SCPHARMACEUTICALS INC (SCPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).
What is the Short Interest ratio of SCPHARMACEUTICALS INC (SCPH) stock?
The outstanding short interest for SCPHARMACEUTICALS INC (SCPH) is 14.39% of its float. Check the ownership tab for more information on the SCPH short interest.
SCPH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SCPH. When comparing the yearly performance of all stocks, SCPH is a bad performer in the overall market: 86.65% of all stocks are doing better.
SCPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SCPH. SCPH has a bad profitability rating. Also its financial health evaluation is rather negative.
SCPH Financial Highlights
Over the last trailing twelve months SCPH reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS decreased by -33.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.19% | ||
| ROE | -639.25% | ||
| Debt/Equity | 3.86 |
SCPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SCPH. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 47.38% and a revenue growth 105.73% for SCPH